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Abstract Acute and chronic inflammatory responses in the
lung are associated with the accumulation of large quantities
of immune and structural cells undergoing apoptosis, which
need to be engulfed by phagocytes in a process called
‘efferocytosis’. Apoptotic cell recognition and removal from
the lung is mediated predominantly by airway macrophages,
though immature dendritic cells and non-professional phago-
cytes, such as epithelial cells and mesenchymal cells, can also
display this function. Efficient clearance of apoptotic cells
from the airways is essential for successful resolution of in-
flammation and the return to lung homeostasis. Disruption of
this process leads to secondary necrosis of accumulating apo-
ptotic cells, release of necrotic cell debris and subsequent un-
controlled inflammatory activation of the innate immune sys-
tem by the released ‘damage associated molecular patterns’
(DAMPS). To control the duration of the immune response
and prevent autoimmune reactions, anti-inflammatory signal-
ling cascades are initiated in the phagocyte upon apoptotic cell
uptake, mediated by a range of receptors that recognise spe-
cific phospholipids or proteins externalised on, or secreted by,
the apoptotic cell. However, prolonged activation of apoptotic
cell recognition receptors, such as the family of receptor tyro-
sine kinases Tyro3, Axl and MerTK (TAM), may delay or
prevent inflammatory responses to subsequent infections. In
this review, we will discuss recent advances in our
understanding of the mechanism controlling apoptotic cell
recognition and removal from the lung in homeostasis and
during inflammation, the contribution of defective
efferocytosis to chronic inflammatory lung diseases, such as
chronic obstructive pulmonary disease, asthma and cystic fi-
brosis, and implications of the signals triggered by apoptotic
cells in the susceptibility to pulmonary microbial infections.
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Cellular turnover occurs as part of the normal homeostatic
process and is vital for the contraction of cells recruited during
an inflammatory response [1]. As with most biological pro-
cesses, it is becoming apparent that turnover of cells is regu-
lated in a tissue-specific manner and this specificity is primar-
ily driven by locally produced factors. For example, the
unique microenvironment of the airspaces drives a distinct
expression pattern of apoptotic cell recognition receptors on
airway macrophages compared to tissue-resident macro-
phages from other anatomical locations [2]. In the airways,
cell turnover is primarily mediated by induction of apoptosis
followed by engulfment of apoptotic cells by phagocytes,
called ‘efferocytosis’. The term ‘efferocytosis’ was coined to
separate engulfment of apoptotic cells from other forms of
phagocytosis and derived from the Latin word ‘effere’ that
translates as ‘take to the grave’. While phagocytosis of path-
ogens requires initiation of an inflammatory response, remov-
al of self-cells that undergo apoptosis is a tolerogenic process
that prevents excessive inflammation and/or autoimmunity
caused by the release of ‘damage associated molecular pat-
terns’ (DAMPS) from apoptotic cells that are not cleared in a
timely manner and undergo secondary necrosis. To achieve
this distinction, macrophages and other phagocytes utilise
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different sets of receptors to recognise microbial particles and
cells undergoing apoptosis, activation of which subsequently
leads to distinct cell activation programmes. Whereas phago-
cytosis of pathogens triggers conserved pro-inflammatory sig-
nalling pathways, engulfment of apoptotic cells by phagocytes
may promote the wound repair process, the production of
factors to curtail inflammation or the secretion of growth fac-
tors to shape a developing tissue. Efferocytosis therefore leads
to different consequences and is a burgeoning focus of re-
search, driven by the discovery of ever more apoptotic cell
recognition receptors and, importantly, pathogens that use the
apoptotic cell clearance process to facilitate their entry into
host cells and/or subvert anti-pathogen immunity.
Mechanisms of efferocytosis
The distinction between apoptotic and healthy cells is medi-
ated primarily by the release of ‘find-me’ signals from apopto-
tic cells that include ATP and UTP [3], fractalkine (CX3CL1)
[4], lysophosphatidylcholine [5] and sphingosine-1-phosphate
[6]. In addition to recruitment, such soluble signals may also
enhance the engulfment capacity of the responding cell. For
example, apoptotic cell production of fractalkine induces milk
fat globule-epidermal growth factor 8 (MFG-E8) expression
in phagocytes that enhances apoptotic cell clearance [7].
Apoptotic cells expose a variety of molecules on their cell
surface that can be recognised by receptors on phagocytic cells.
The precise composition of such ‘eat-me’ signals likely depends
on whether apoptosis is occurring under homeostatic conditions
or during inflammation and is tissue- and cell type-specific [1,
8]. One of the best studied ‘eat-me’ signals is phosphatidylserine
(PtdSer) that in living cells is localised to the inner leaflet of the
plasma membrane and is externalised upon induction of apopto-
sis [9]. Overexpression of PtdSer enhances apoptotic cell engulf-
ment, whereas PtdSer blockade suppresses this process, leading
to autoimmunity [10, 11]. Irreversible externalisation occurs
when caspases inactivate flippase (ATP11C) that in healthy cells
continually flips PtdSer in the plasma membrane [12]. At the
same time, caspase-dependent activation of scramblases (such as
Xkr8), which non-specifically and bi-directionally scramble
phospholipids in the plasma membrane, is also required for
PtdSer exposure on apoptotic cells [13]. PtdSer is transiently
exposed on the surface of living cells that resist efferocytosis,
suggesting that this signal alone may not be enough, or that
prolonged interaction of PtdSer receptors on phagocytes is re-
quired [14]. Oxidised low-density lipoprotein, calreticulin,
annexin A1, ICAM3, C1q and thrombospondin-1 (TSP1) are
also implicated in efferocytosis [1]. Furthermore, healthy cells
prevent engulfment by expressing CD47 and CD31 [15, 16] or
by ligating CD300a that impedes macrophage function [17]. A
balance of efferocytosis-inducing and inhibitory signals may
therefore determine apoptotic cell clearance.
PtdSer and other ‘eat-me’ signals exposed on apoptotic
cells bind a plethora of receptors on phagocytic cells, a num-
ber of which have been identified in the lung (Table 1).
Externalised PtdSer is recognised directly by triggering recep-
tor expressed by myeloid cells-2 (TREM2) [30], CD300 [31],
receptor for advanced glycation end products (RAGE) [32],
stabilin-2 [33], brain-specific angiogenesis inhibitor-1 (BAI1)
[34] and the family of T cell/transmembrane, immunoglobu-
lin, and mucin (TIM) receptors, which includes TIM-1, 3 and
4 [35, 36]. Other engulfment receptors require bridging mol-
ecules to link them to externalised PtdSer. For example,
integrin αvβ3 or αvβ5 requires MFG-E8, while Tyro3, Axl
and MerTK that form the TAM receptor tyrosine kinase fam-
ily [37] require the bridging molecules Protein S or growth
arrest specific 6 (Gas6) [38]. The N-terminal Gla domains of
Protein S and Gas6 bridge TAM receptors to PtdSer on the
surface of apoptotic cells [39], whereas the C-terminal sex
hormone-binding globulin-like domains bind and activate
the TAM receptor [40]. There are also a number of receptors
that recognise other externalised ligands including scavenger
receptor class F, member 1 (SCARF1) and LDL receptor-
related protein-1 (LRP-1, also known as CD91) that recognise
C1q and calreticulin, respectively, CD36 together with
integrin αvβ3 or αvβ5 that recognises TSP-1, CD14 that
binds a modified form of the intracellular adhesion molecule
ICAM3, and lectin receptors that recognise altered sugars [1].
The logic behind possessing so many receptors that can
recognise apoptotic cells is not entirely clear. Some, such as
TIM-4, act as tethering receptors without any signalling con-
sequences [41], similar to CD14 [42]. Different receptors may
also act at different stages of efferocytosis [43] or may prefer-
entially clear cells in different locations. For example, TREM2
and TREM2-L form a receptor-ligand pair connectingmicrog-
lia with apoptotic neurons, directing removal of damaged cells
to allow repair [44]. It is also likely that an alternate outcome is
required upon efferocytosis that requires linkage to different
signalling components [31]. With regard to the TAM recep-
tors, MerTK is ubiquitously expressed on macrophages and
even used as a defining marker for them. Airway macro-
phages, however, unlike most other macrophages, constitu-
tively express Axl, possibly due to the local environment that
is rich in granulocyte-macrophage colony-stimulating factor
(GM-CSF) [2]. Importantly, receptors that recognise apo-
ptotic cells can also play a dual function: inducing the
cytoskeletal rearrangements necessary to ingest the apopto-
tic cell and also transmitting an instructive signal [45]. It is
interesting to note that individual TAM receptor family
members use different molecules to bridge them to
PtdSer externalised on apoptotic cells: MerTK and Tyro3
are activated by both Gas6 and Protein S, whereas the sole
ligand for Axl is Gas6 [46, 47]. In the case of MerTK and
Tyro3, it is therefore possible that specific signals triggered
by receptor ligation might differ depending on the bridging
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molecule, though this possibility remains to be verified
experimentally. Finally, further selectivity of response is
afforded by co-operation of multiple receptors such as Axl
and LRP-1 on dendritic cells where Axl tethers the apoptotic
cell to dendritic cells, but LRP-1 is required to trigger
internalisation [48].
Impact of efferocytosis on cell function
The receptors that mediate efferocytosis often have anti-
inflammatory signalling consequences that can change the
phenotype and function of the ingesting cell. For example,
engagement and activation of TAM receptors inhibits signal-
ling pathways triggered by cytokines and toll-like receptor
ligands through induction of suppressor of cytokine
signalling-1 and 3 (SOCS-1 and 3) [49, 50] (see Fig. 1a, b).
The impact of apoptotic cell clearance on cell function de-
pends on the cell type mediating efferocytosis, which in turn
depends on tissue location. In the lung, efferocytosis is medi-
ated predominantly by macrophages and airway epithelial
cells, with most consequences studied in the former. In mac-
rophages, efferocytosis increases the secretion of the anti-
inflammatory cytokines, transforming growth factor-β
(TGF-β) and interleukin (IL)-10 [51, 52], while inhibiting
secretion of proinflammatory mediators such as TNF-α, IL-
1, IL-8 and leukotriene C4 [53, 54]. IL-10 production by
macrophages upon apoptotic cell contact is, in part,
dependent upon the scavenger receptor CD36 [51] and
TSP-1, which links macrophages to apoptotic cells in coop-
eration with integrin αvβ3 [55]. Efferocytosis also
upregulates prostaglandin E2 (PGE2) and impairs FcR-
mediated phagocytosis [54, 56], and intratracheal instil-
lation of apoptotic cells enhances the resolution of LPS-
induced acute pulmonary inflammation [57]. This change
in function from pro-inflammatory to pro-resolution can be ob-
served as a phenotypic switch from an M1- to an M2-like mac-
rophage phenotype and includes the induction of peroxisome
proliferator-activated receptor-γ (PPARγ) [58]. However, this
is likely to be context-, cell-type- and tissue-dependent. For
example, nitric oxide, but not IL-10, TGF-β or PGE2, mediates
the immunosuppressive effects induced by apoptotic cell
efferocytosis in dendritic cells [59]. It is also interesting to
note that efferocytosis by dendritic cells appears to be
subset-specific. Only CD103+ murine lung dendritic cells
capture and present apoptotic cell-associated antigen in
health and disease, whereas both the CD11bhi and the
CD103+ dendritic cells ingest and traffic latex beads or
soluble antigen [60]. Whether this is due to selective ex-
pression of receptors recognising apoptotic cells or a phe-
notypic switch after ingestion is not currently known.
Therefore, clearance of apoptotic cells has profound influ-
ences on the ingesting cell. Though the outcome has pre-
dominantly been studied for macrophages, other cell
types, particularly dendritic cells, are also likely to be
affected.
Table 1 ‘Eat-me’ signals





Receptor Receptor expression on
airway macrophages
PtdSer TIM family (TIM-1, 3 and 4) Not studied
TAM family (Tyro3, Axl, MerTK)
through Gas6 and Protein S
High Axl and MerTK expression
in mice, only MerTK studied and
confirmed in humans [2, 18]
BAI1 Not studied
RAGE Confirmed in mice [19] and humans [20]
Stabilin-2 Not studied
Integrin αvβ3 or αvβ5 through MFG-E8 Low αvβ3 expression in humans [21, 22]
TREM2 Confirmed in mice [23] and humans [24]
TSP-1 CD36 (in complex with integrin αvβ3 or αvβ5) Confirmed in humans [21, 25]
ICAM3 CD14 Low expression in mice [26]
and humans [27]
Altered sugars Lectin receptors Mannose receptor confirmed in mice [26]
and humans [28]
Calreticulin LRP-1/CD91 Confirmed in mice [29] and
humans [22, 29]
C1q SCARF1 Not studied
BAI1 brain-specific angiogenesis inhibitor-1, ICAM3 intracellular adhesion molecule-3, LRP-1 LDL receptor-relat-
ed protein-1, MFG-E8 milk fat globule-epidermal growth factor 8, PtdSer phosphatidylserine, RAGE receptor for
advanced glycation end products, TSP-1 thrombospondin-1, SCARF1 scavenger receptor class F, member 1, TIM T
cell/transmembrane, immunoglobulin, and mucin, TREM2 triggering receptor expressed on myeloid cells-2
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Cell turnover and clearance in the lung
In any tissue, cell turnover is a natural homeostatic process
and occurs predominantly by apoptosis before loss of plasma
membrane integrity. Timely removal of these apoptotic cells is
critical to prevent autoimmune reactions to cellular constitu-
ents. However, the speed of turnover determines the require-
ments for the local phagocytic system in terms of its capacity
to clear the accumulating apoptotic cells and is often governed
by the local microenvironment and past inflammation history.
In healthy murine and human lungs, airway macrophages
make up 95 % of cells retrieved by bronchoalveolar lavage
[2, 61]. They exist in a tolerant state due to interaction with
proteins and receptors expressed by or secreted from the
respiratory epithelium. Furthermore, mucus bathing the epi-
thelium contains surfactant proteins that dampen macrophage
responsiveness in health [62]. Chimeric mouse experiments
show that resident airway macrophages have an unusually
prolonged life span with negligible turnover even at 8 months
in the absence of inflammation. This situation changes follow-
ing their depletion during inflammation where replenishment
from the periphery occurs, leading to a population of macro-
phages that are reported to have a shorter life span. Airway
macrophage removal by irradiation leads to replenishment
from the periphery and a higher turnover rate of approximate-
ly 30 days [63]. However, the fate of resident airway mac-
rophages following pulmonary infection is not entirely
clear. One study shows that macrophages recruited to the
Fig. 1 The many roles of apoptotic cell recognition and phagocytosis in
immunity and infection. a Efferocytosis leads to removal of apoptotic
cells without release of their content. When apoptotic cells are not
engulfed in a timely manner, they undergo secondary necrosis and
release necrotic cell debris which subsequently causes uncontrolled
inflammatory activation of the innate immune system by the released
‘damage associated molecular patterns’ (DAMPS). b During apoptosis,
cells expose phosphatidylserine (PtdSer) on the outer leaflet of their
membranes, which is recognised by specific receptors expressed on
phagocytes. Recognition of PtdSer by TAM receptors through bridging
molecules Gas6 and Protein S triggers a signalling cascade which
converges on upregulation of suppressor of cytokine signalling-1 and 3
(SOCS3), which act as negative regulators of the immune response.
Activation of TAM receptors by apoptotic cells inhibits production of
proinflammatory cytokines, such as TNFα and IL-6, while promoting
expression of factors that suppress inflammation and promote tissue
repair, including IL-10 and TGF-β. c Some enveloped viruses express
PtdSer on their envelopes and use PtdSer recognition receptors, such as
TAM and TIM receptor families, to promote infection of the host cells
and evade the immune response. d During microbial infections with
intracellular pathogens, induction of apoptosis of infected cells is one of
the strategies of the host immune system to facilitate pathogen clearance.
For example, in case of Mycobacterium tuberculosis (Mtb) infections,
necrosis of infected cells leads to dissemination of bacteria, whereas
engulfment of infected cells undergoing apoptosis allows for pathogen
destruction
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airways from the periphery during influenza infection con-
tract by Fas-dependent apoptosis, while the number of resi-
dent airway macrophages remains unchanged [64], whereas
another implies significant ablation of resident airway mac-
rophages followed by replenishment from the interstitial
pool [65]. Discrepancy might arise from the use of intranasal
dye (that becomes diluted on cell division) or the depletion
by irradiation with the lung protected by lead. In order to
track definitively the fate of airway macrophages following
influenza infection, the Flt3-Cre ×Rosa26-LSL-YFP report-
er mice would be useful as all bone marrow emigrants be-
come YFP expressing and so mice do not require prior ma-
nipulation to distinguish resident versus recruited airway
cells [66]. Like airway macrophages, epithelial cells similar-
ly have a long half-life in health. Using reporter mice where
ciliated cells and their progeny can be tracked across their
lifetime, a half-life of 6 months in the trachea and 17 months
in the bronchioles and terminal bronchioles has been esti-
mated [67].
Taken together, these observations indicate that in homeo-
stasis relatively small quantities of apoptotic cells appear in
the airways due to slow turnover of the main cell populations
residing in the healthy lung. It is therefore not surprising that
lung phagocytes efficiently clear these scarce apoptotic cells
even when their efferocytic function is partly disrupted. For
example, deletion of Axl, which is highly expressed on mu-
rine airway macrophages, does not cause accumulation of
necrotic cell debris and lung inflammation in the absence of
accompanying infection despite significant impairment of the
efferocytic function of airway macrophages [2]. Similarly,
blockade of apoptotic cell uptake by airway epithelial cells
through cell type-specific deletion of the small GTPase
Rac1, which is required for efferocytosis mediated by several
classes of engulfment receptors, does not affect the integrity
and responses of the epithelial barrier without administration
of exogenous apoptotic cells or induction of allergic airway
inflammation [68].
Defective efferocytosis in chronic lung diseases
In health, apoptotic cells are essentially undetectable in the
lung tissue [69], and immune cells infiltrating the airways
which undergo apoptosis are rapidly cleared by airway mac-
rophages in models of acute microbial infection-related lung
inflammation [70]. Respiratory infections are therefore not
associated with persistent accumulation of large quantities of
apoptotic cells in the airspaces. However, increased numbers
of dying cells are detected in the airspaces of patients with
several aetiologically distinct chronic inflammatory lung dis-
eases [71]. Although higher frequencies of apoptotic cells in
these diseases might result either from elevated rates of apo-
ptotic cell death or defects in apoptotic cell removal,
experimental evidence suggests that reduced efficiency of
efferocytosis, predominantly by airway macrophages, plays
a key role in this pathological process [72, 73].
Chronic obstructive pulmonary disease
The most comprehensive analysis of defects in apoptotic cell
clearance has been performed in chronic obstructive pulmo-
nary disease (COPD), which is a chronic lung disease
characterised by un-resolving inflammation due to accumula-
tion of activated neutrophils and T cells causing small-airway
obstruction, peribronchial fibrosis and/or destruction of air-
way walls (emphysema). These pathological processes lead
to progressive destruction of lung parenchyma and, as a con-
sequence, airflow limitation that is not fully reversible in pa-
tients with emphysema, and in other subtypes of COPD [74].
Historically, lung pathology in COPD was attributed to al-
terations in the protease/anti-protease balance and oxidative
stress caused by cigarette smoking, which is the main risk
factor for COPD. However, there is evidence that indicates
an important role of aberrant apoptosis and apoptotic cell
clearance in the lung damage observed in COPD [75].
Several reports demonstrate accumulation of apoptotic epi-
thelial, endothelial and immune cells in the lungs of patients
with COPD and/or emphysema [69, 76, 77], and induction
of structural airway cell apoptosis is sufficient to cause em-
physematous changes in mice [78].
In a series of elegant studies, Hodge and co-workers dem-
onstrate that increases in the numbers of apoptotic cells de-
tected in the lungs of patients with COPD can be attributed to
significantly impaired efferocytic function of airway macro-
phages. Uptake of apoptotic bronchial epithelial cells and neu-
trophils is significantly reduced in bronchoalveolar lavage
macrophages from patients with COPD compared to healthy
controls [21, 22, 79], and this defect is more pronounced in
COPD patients who currently smoke [22]. The observed re-
ductions in efferocytic potential of airway macrophages
in vitro correlate with the frequency of apoptotic bronchial
epithelial cells isolated from bronchial brushings and are as-
sociated with altered expression of several proteins involved
in apoptotic cell recognition and binding, including CD31,
CD44 and LRP-1/CD91 [22]. Intriguingly, restoration of
COPD airway macrophage efferocytic function by the
macrolide antibiotic azithromycin does not correlate with
changes in expression of these molecules [21]. Instead, it
depends on PtdSer binding by airway macrophages [21],
suggesting that deregulation of PtdSer-recognising receptors
or bridging molecules might be responsible for defective ap-
optotic cell removal in COPD. Neither TAM nor TIM fami-
lies of PtdSer recognition receptors have been studied in
COPD so far but, surprisingly, increased expression of
MerTK is observed on airway macrophages from cigarette
smokers [18], which are also characterised by impaired
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apoptotic cell uptake compared to cells from healthy non-
smokers [18, 22]. This observation indicates that upregula-
tion of MerTK is not sufficient to restore the efforocytic
function of airway macrophages to normal levels and other
PtdSer receptors, such as Axl, which is highly expressed on
mouse airway macrophages [2], might play a more promi-
nent role.
Apart from potential alterations in PtdSer receptor ex-
pression and function, which require more detailed studies,
several other mechanisms might be involved in
efferocytosis defects observed in COPD. Significant im-
pairment of apoptotic cell uptake by airway macrophages
from smokers indicates an important role of oxidative
stress caused by cigarette smoke components in this pro-
cess [18, 22]. In mice, cigarette smoke exposure, which is
sufficient to induce emphysema [80], significantly sup-
presses efferocytosis by airway macrophages in vivo and
in vitro, and this effect is reversible by treatment with
antioxidants or overexpression of extracellular superoxide
dismutase [81, 82]. Macrophage phagocytosis of apoptotic
cells is also inhibited by the alarmin high mobility group
protein-1 (HMGB1) [83, 84], and elevated levels of
HMGB1 both in the airways and peripheral blood of pa-
tients with COPD have recently been reported, negatively
correlating with patient lung function [20, 85]. Since ne-
crotic cells are the main source of extracellular HMGB1, a
positive feedback loop might exist in COPD where apo-
ptotic cells undergo secondary necrosis and release
HMGB1, which further impairs the efferocytic function
of airway macrophages. This in turn would lead to accu-
mulation of greater amounts of necrotic debris and perpet-
uation of chronic inflammation. Finally, engulfment of ap-
optotic cells by macrophages is also regulated by the
members of the collectin family of C-type lectins. The
levels of mannose-binding lectin (MBL), which promotes
apoptotic cell uptake in vitro [86], are reduced in the
airways of patients with COPD and correlate with im-
paired macrophage efferocytosis [87, 88]. Surfactant pro-
tein A (SP-A) and SP-D, on the other hand, play a more
complex role in apoptotic cell recognition in the lung.
While homeostatic interaction of SP-A or SP-D with sig-
nal inhibitory regulatory protein-α (SIRPα) expressed on
airway macrophages suppresses efferocytosis [89],
opsonisation of apoptotic cells by SP-A or SP-D and in-
teraction of this complex with LRP-1/CD91 enhances ap-
optotic cell uptake [29, 90]. The latter seems to play a
more prominent role during chronic lung inflammation as
SP-D levels are significantly reduced in patients with
COPD [28, 91], potentially contributing to efferocytosis
defects. Alternatively, downregulation of SP-D might rep-
resent a physiological response of the lung aimed at over-
coming SIRPα-dependent suppression of macrophage
efferocytic function in the presence of large amounts of
dead cells, which fail to efficiently remove apoptotic cells
from the COPD airways due to other phagocytosis defects.
Asthma
Asthma is an obstructive airway disease characterised by
hyper-responsiveness and chronic inflammation of the respi-
ratory tract. While neutrophils are a predominant cell type in
the lungs of COPD patients, asthma represents eosinophil-
dominant airway inflammation. Initial priming of the adaptive
immune system by airway allergens leads to the activation of
tissue-resident mast cells, which release a broad array of in-
flammatory mediators promoting migration of eosinophils in-
to the airways [92]. Products of eosinophil degranulation, in-
cluding major basic protein, eosinophil cationic protein and
reactive oxygen species, are cytotoxic to epithelial cells and
cause airway damage and tissue remodelling. Indeed, in-
creased numbers of apoptotic epithelial cells have been detect-
ed in the lungs of patients with asthma compared to healthy
individuals [93]. Apoptosis and subsequent uptake by phago-
cytes appear to be a predominant mechanism of eosinophil
removal from the airways [94, 95], and glucocorticoids, which
are commonly used to control inflammation in asthma, induce
eosinophil apoptosis [96]. These observations indicate that
high efficiency of the phagocytic system is required for re-
moval of large quantities of apoptotic eosinophils and bron-
chial epithelial cells from the airways of patients with asthma
and raise the possibility that defects in efferocytosis might
prevent resolution of lung inflammation.
Initial studies byHyunh et al. demonstrate that airwaymac-
rophages from patients with severe asthma contain reduced
numbers of phagocytic bodies compared to healthy donors
and patients with mild/moderate asthma and are defective in
phagocytosing apoptotic Jurkat T cells in vitro [97]. Failure of
airway macrophages from patients with severe asthma to effi-
ciently clear apoptotic cells is associated with reduced produc-
tion of anti-inflammatory eicosanoids [97], suggesting that
defects in efferocytosis might contribute to perpetuation of
inflammation in asthma, not only through secondary necrosis
of apoptotic cells, but also by reduced release of regulatory
mediators that are normally produced upon recognition of
apoptotic cells by airway macrophages. More recently, it
has been shown that efferocytosis of apoptotic bronchial
epithelial cells by airway macrophages isolated from in-
duced sputum of patients with non-eosinophilic asthma is
significantly reduced compared with patients with eosino-
philic asthma, and the degree of uptake impairment is com-
parable to that observed in COPD [98]. This observation
might partly explain the persistent neutrophilia and aberrant
innate immune responses in this subgroup of patients [99].
Efferocytosis defects in asthma are associated not only with
the subtype of airway inflammation but also with the BMI
index: airway macrophages from obese patients with
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asthma, which typically suffer from more severe disease
symptoms [100], are characterised by significantly reduced
numbers of phagocytic bodies compared to non-obese asth-
matics [101]. Notably, defective efferocytic function in
obese asthmatics is not restricted to the site of inflammation
as decreased uptake of beads mimicking apoptotic cells is
also observed in peripheral blood monocytes isolated from
these patients, correlating with reduced glucocorticoid re-
sponsiveness [101].
While these reports provide clear evidence that removal of
apoptotic cells is defective in asthma, in particular in certain
disease subtypes, additional studies are needed to characterise
the molecular mechanisms underlying the observed defects.
Even though potential changes in expression and function of
receptors recognising apoptotic cells on airway macrophages
have not been formally studied in asthma, it is important to
note that the TIM receptor family member TIM-1, which is
preferentially expressed on specific lymphocyte populations,
is an important susceptibility gene for allergic asthma [102].
Targeting TIM-1 modulates airway inflammation in mouse
models of airway hyper-responsiveness at least in part through
TIM-1-dependent interaction of NKT cells with PtdSer on the
surface of apoptotic cells [103, 104]. These observations sug-
gest that recognition of PtdSer by immune cells that do not
phagocytose apoptotic cells also has profound effects on the
development of chronic lung inflammation. They also indicate
that future studies of molecules involved in apoptotic cell
binding in asthma should not be restricted to analyses of air-
way macrophages as the main contributors to apoptotic cell
clearance from the inflamed airways. Interestingly, not only
efferocytosis but also engulfment of bacteria by airway mac-
rophages is impaired in asthma [105]. This finding indicates
that alterations in the intracellular molecular machinery regu-
lating phagocytosis rather than changes in expression of re-
ceptors recognising apoptotic cells might be responsible for
the observed phagocytosis defects.
Finally, while previous studies have solely focused on
efferocytosis by airway macrophages, mounting evidence
suggests that bronchial epithelial cells might be equally
important in clearing apoptotic cells from the inflamed
airways. Even though epithelial cells are not professional
phagocytes, they efficiently engulf apoptotic eosinophils,
but not neutrophils [94, 106]. Animal studies demonstrate
a critical role for airway epithelial cells in the removal of
apoptotic cells from the inflamed lung and, as a conse-
quence, control of inflammatory responses in the murine
model of allergic airway hyper-responsiveness [68].
Future studies in humans are therefore necessary to char-
acterise the relative contributions of airway macrophages
and bronchial epithelial cells to defects in apoptotic cell
removal in asthma and to identify therapeutic strategies
which could restore and/or promote the efferocytic func-
tion of both cell types, as well as activate anti-
inflammatory transcriptional programmes associated with
apoptotic cell recognition.
Cystic fibrosis
Cystic fibrosis (CF) is a heritable disorder caused by mutation
in the CF transmembrane conductance regulator (CFTR) and
characterised by severe pulmonary manifestations. Impaired
mucociliary clearance in CF patients prevents elimination of
bacteria from the lung, leading to persistent neutrophilic in-
flammation and progressive, irreversible damage of the air-
ways [107]. Similar to other lung diseases associated with
chronic inflammation, both accumulation of apoptotic cells
in the airways and reduced numbers of phagocytic bodies
within sputum macrophages are observed in patients with
CF compared to control patients with chronic bronchitis
[25]. Mechanistically, degranulation products of immune cells
are partly responsible for efferocytosis defects in CF as neu-
trophil elastase present in the airway fluid of CF patients se-
lectively cleaves PtdSer recognition receptors and suppresses
apoptotic cell removal by airway macrophages [25]. Other
potential mechanisms contributing to impaired apoptotic cell
clearance in CF involve the release of HMGB1 which, similar
to COPD, is elevated in sputum samples from CF patients
[108] and effects of bacterial products on airway macro-
phages. Pseudomonas aeruginosa infections are common in
CF and represent an important cause of mortality in CF lung
manifestations. In vitro, P. aeruginosa toxic metabolite pyo-
cyanin and the polysaccharide alginate inhibit apoptotic cell
uptake by macrophages [109, 110], though the relevance of
this mechanism in patients has yet to be demonstrated.
Interestingly, animal studies indicate that airway epithelial
cells in CF might also be deficient in phagocytic functions.
While defective efferocytosis by airway macrophages in
CF patients is a consequence of the ongoing inflammatory
response and/or microbial infection, impaired apoptotic cell
uptake by epithelial cells might be directly related to the lack
of CFTR expression. CFTR-deficient epithelial cells express
significantly increased levels of RhoA, which is a negative
regulator of efferoctyosis, and RhoA inhibition restores their
phagocytic function [111]. It remains to be determined if a
similar mechanism regulates bronchial epithelial cell
efferocytosis in patients with CF.
Pulmonary fibrosis
Elevated levels of apoptotic cells and reduced frequencies of
phagocytic bodies within bronchoalveolar lavage macro-
phages have also been reported in patients with idiopathic
pulmonary fibrosis (IPF) [112]. IPF is an interstitial lung dis-
ease characterised by epithelial injury that is followed by ab-
errant alveolar wound repair and scar formation, which ulti-
mately lead to respiratory failure and death. IPF is frequently
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accompanied by chronic neutrophilic inflammation [113].
Interestingly, intratracheal instillation of apoptotic cells ame-
liorates fibrosis and inflammation in bleomycin-induced lung
injury in mice [58, 114], indicating that signalling triggered by
apoptotic cell recognition may play a protective role in lung
diseases associated with dysregulated healing processes. The
anti-fibrotic effects of apoptotic cells in this model are depen-
dent on the induction of PPARγ expression in airway macro-
phages and increased production of hepatocyte growth factor
(HGF), which plays a key role in alveolar epithelial repair
upon lung injury [58, 114]. These observations suggest that
defects in efferocytosis in IPF patients may be responsible not
only for inefficient clearance of apoptotic cells but also for
diminished production of factors that support tissue repair
without fibrosis.
Collectively, the data from patients with asthma, COPD,
CF and pulmonary fibrosis indicate that defective apoptotic
cell clearance in lung diseases is not specific for individual
diagnoses but rather represents a general hallmark of chronic
inflammation. Although several mechanisms contributing to
these defects have been proposed, it remains to be verified
whether impairment of efferocytosis might be a direct cause
of chronic inflammation, or is a consequence to the ongoing
inflammatory processes that contributes to chronicity and pre-
vents resolution. The latter model is supported by the obser-
vation that mice lacking the TAM receptor Axl do not develop
spontaneous lung inflammation despite defects in apoptotic
cell uptake by airway macrophages [2], but more detailed
analyses of regulation and function of PtdSer recognition re-
ceptors in the human lung are required. Finally, because rec-
ognition of apoptotic cells by PtdSer-recognising receptors
activates downstream signalling pathways even without en-
gulfment [46], future studies are needed to verify whether
activation of transcriptional programmes triggered by recog-
nition of apoptotic cells is also altered in chronic lung diseases
and, if so, how they can be manipulated in the clinic by spe-
cific modulators of PtdSer recognition receptors.
Efferocytosis in microbial infection of the lung
While in sterile inflammation recognition of apoptotic cells by
the immune system typically results in suppression of the
ongoing inflammatory response, the complexity of this pro-
cess and its biological effects greatly increase in the context of
microbial infections. First, some enveloped viruses use PtdSer
receptors to promote their entry into the host cells and facili-
tate infection and immune evasion [115]. The interaction be-
tween PtdSer exposed on the surface of the viral envelope and
members of the TAM and TIM receptor families expressed on
the target cell enables proximity to specific entry receptors and
enhances engulfment of the virus [116] (Fig. 1c). The rele-
vance of this process, called ‘apoptotic mimicry’, has recently
been confirmed for a broad range of virions, including Ebola
and dengue viruses [117, 118]. Thus far, however, little is
known about potential roles of this entry mechanism in pul-
monary viral infections. The observation that the kinetics of
influenza H1N1 virus clearance was unaffected in Axl-
deficient mice indirectly indicates that Axl is not important
for control of this infection [2], though Axl-H1N1 interaction
has not been formally tested. Similarly, although TIM1 pro-
motes internalisation and replication of several enveloped vi-
ruses, TIM1-mediated entry does not lead to a productive
infection by influenza H7N1 and severe acute respiratory syn-
drome (SARS) coronavirus [117], arguing against an impor-
tant role of apoptotic mimicry in viral lung diseases.
Second, many pathogens survive intracellularly, and
phagocytosis of infected host cells undergoing apoptosis has
diverse consequences for pathogen survival and immune re-
sponse of the host [119]. One of the main strategies of the
immune system to control intracellular infections is through
induction of apoptosis of infected cells, which are then
engulfed and destroyed together with the pathogen by phago-
cytes (Fig. 1d). However, in some cases, efferocytosis of in-
fected cells is used by intracellular pathogens, such as the
parasite Leishmania major, to evade the immune response
and gain entry into the new cellular host [119]. Among path-
ogens important in respiratory diseases, the role of
efferocytosis has been most thoroughly studied in the context
ofMycobacterium tuberculosis infections.M. tuberculosis in-
fects macrophages and induces necrosis of the host cell to
avoid clearance by the immune system and disseminate
[120]. Interestingly, M. tuberculosis-infected mouse macro-
phages which die by apoptosis are rapidly efferocytosed by
uninfected macrophages, leading to bacterial killing and elim-
ination [121]. This bactericidal effect is dependent on
efferocytosis, as the uptake of naked M. tuberculosis does
not allow for lysosome recruitment to the bacteria-
containing phagosome, and inhibition of apoptotic cell uptake
with a TIM-4-blocking antibody prevents bacterial control
in vitro and increases bacterial burden in the lungs in vivo
[121]. The observation that bactericidal activity of macro-
phages infected with Streptococcus pneumoniae is dependent
on induction of macrophage apoptosis suggests that a similar
mechanism might be involved in controlling infection with
this bacterium [122], though the involvement of efferocytosis
in this process has not been formally proven. Engulfment of
macrophage-derived apoptotic vesicles also plays a critical,
though indirect, role in the adaptive immune response against
M. tuberculosis: annexin A1-dependent uptake of apoptotic
cells by dendritic cells is required for cross-presentation and
generation of M. tuberculosis-specific CD8 T cell response
and bacterial clearance from the lung [123].
The antimicrobial role of apoptotic cell clearance in pul-
monary infections is not restricted to bacteria as the influenza
Avirus induces apoptosis of epithelial cells upon infection and
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engulfment of influenza A-infected cells by macrophages is
associated with reduction of viral titres [124]. On the other
hand, infection of macrophages with Francisella novicida, a
member of the Francisellaceae family of intracellular bacteria
which cause pulmonary inflammation associated with necrot-
ic infiltrates in the lung, reduces their efferocytic function,
potentially contributing to the accumulation of necrotic cell
debris and exacerbation of disease [125].
Taken together, these studies suggest that efferocytosis is
not only a constitutive function of macrophages required for
maintaining immune homeostasis in health and during inflam-
matory response but also an important antimicrobial effector
mechanism. However, it has to be noted that apart from bac-
tericidal activity against specific pathogens, the anti-
inflammatory signal associated with apoptotic cell uptake by
phagocytes might prevent the mounting of an efficient im-
mune response in the context of other lung infections. Prior
exposure of mouse airway macrophages to apoptotic cells
results in suppression of FcR-mediated phagocytosis and kill-
ing of bacteria, and intrapulmonary administration of apopto-
tic cells causes significant impairment of S. pneumoniae clear-
ance from the infected lung [56]. Suppression of antimicrobial
responses of airway macrophages is also augmented by glu-
cocorticoids, which promote efferocytosis, and treatment of
mice with apoptotic cells in the presence of glucocorticoids
is associated with elevated bacterial burden in the lungs [126].
Even though validation of these observations in human sys-
tems is necessary, they clearly indicate that efferocytosis plays
a dual role in lung infections: while efficient apoptotic cell
uptake is required for resolution of the inflammatory response
and elimination of certain intracellular pathogens, the anti-
inflammatory programmes activated upon prolonged expo-
sure to apoptotic cells might increase susceptibility to second-
ary infections and infection-related exacerbations of chronic
inflammatory lung diseases.
Targeting defective apoptotic cell clearance in lung
diseases
In light of the importance of effercotysis in resolution of in-
flammation and the reported defects in apoptotic cell removal
in chronic inflammatory lung diseases, it is not surprising that
evaluation of potential therapeutic strategies aimed at enhanc-
ing apoptotic cell uptake gained a lot of attention in recent
years [72, 73]. Strikingly, glucocorticoids, which are the most
commonly used class of drugs in the treatment of asthma and
COPD, increase apoptotic cell engulfment by macrophages
in vitro [127] and restore the efferocytic function of airway
macrophages from patients with severe asthma [97].
Upregulation of the TAM receptor MerTK [128, 129] and
downregulation of SIRPα [130] might be responsible for the
pro-efferocytic activity of glucocorticoids in macrophages.
However, it remains unknown whether promotion of apopto-
tic cell clearance significantly contributes to the anti-
inflammatory effects of glucocorticoids in patients with lung
diseases. More systematic analyses of apoptotic cell accumu-
lation and efferocytic functions of airway macrophages before
and after glucocorticoid therapy in responders and non-
responders are therefore necessary to address this question.
Some classes of medications widely used in the clinic for
other indications also promote efferocytosis. The antibiotic
azithromycin increases phagocytosis of apoptotic cells by hu-
man airway macrophages in vitro [21, 131], and significant
improvement of the efferocytic function of airway macro-
phages from COPD patients after oral treatment with
azithromycin has been reported [28]. In light of recent evi-
dence that azithromycin reduces the frequency of exacerba-
tions in COPD patients [132], it is tempting to speculate that at
least part of the immunomodulatory activities of macrolide
antibiotics can be attributed to their effects on apoptotic cell
clearance. Similarly, PPARγ agonists, which are used as insu-
lin sensitizers in diabetes mellitus, but also display broad anti-
inflammatory effects, promote efferocytosis by airway macro-
phages in vitro and ameliorate disease symptoms in animal
models of pulmonary inflammation [133, 134]. Enhancement
of apoptotic cell engulfment is also observed after treatment of
macrophages from COPD patients with simvastatin [135], a
member of the statin family of cholesterol-lowering drugs,
and retrospective studies suggested that statins might reduce
the risk of COPD exacerbations and mortality [136, 137].
More recently however, in a large randomised clinical trial,
simvastatin treatment had no effect on exacerbation rates in
COPD patients [138], though the efferocytic function of air-
way macrophages was not analysed in this study. It remains an
open question if patients with COPD can be stratified to iden-
tify a subgroup of patients that responds to statin treatment and
whether this is related to effects on apoptotic cell clearance.
Finally, the observations that aberrant expression and ac-
tivity of the TAM receptor Axl has an oncogenic function in
haematological and epithelial malignancies triggered the in-
terest in targeting the activity of PtdSer recognition receptors,
and a small molecule inhibitor of Axl is currently in phase I
clinical trials [139]. However, preclinical studies indicate that
pharmacological modulators of PtdSer recognition receptors
might have a significant impact on the immune system, espe-
cially in the context of lung immunopathology. In light of the
critical role of Axl in resolution of lung inflammation upon
influenza infection [2], any attempts to target Axl activity
systemically should proceed with caution due to potential ad-
verse events related to exaggerated inflammatory responses to
respiratory infections. Similar to Axl, MerTK signalling is
also required for silencing of lung inflammation: inhibition
of MerTK proteolytic cleavage by the ADAM17 inhibitor
TAPI-0 restores MerTK expression and attenuates inflamma-
tion during LPS-induced lung injury [140], whereas
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administration of aMerTK blocking antibody has the opposite
effect [141]. These results suggest that activating antibodies or
compounds which prevent shedding of TAM receptors could
be beneficial in the context chronic lung diseases. Indeed,
TAM receptors can be activated independently of apoptotic
cell engulfment by specific antibodies [46, 142], though their
effects have not been tested in models of lung inflammation.
In that regard, it is noteworthy that activation of TAM recep-
tors leads to shedding of their extracellular domains and sol-
uble forms of TAM receptors can act as decoy receptors and
suppress apoptotic cell engulfment by macrophages [143].
Although alterations in the levels of soluble TAM receptors
are noted in several pathologies [144, 145], their physiological
role is still poorly understood. It remains unknown if admin-
istration of antibodies targeting TAM receptors would cause
their sequestration and what consequences it would have for
the immune homeostasis of the lung.
Conclusions
Since the initial discovery of defects in apoptotic cell clear-
ance in asthma and COPD, great progress has been made in
our understanding of the molecular mechanisms of
efferocytosis and several new processes through which
efferocytosis modulates host immune responses have been
characterised (Fig. 1). Consequently, new questions have
emerged regarding the role of apoptotic cell removal in lung
homeostasis and the most important of them are listed in Box
1. Future studies addressing these questions, especially at-
tempts to therapeutically manipulate efferocytosis in the clin-
ic, should be designed in the context of the multiple roles of
apoptotic cell phagocytosis in resolution of inflammation and
microbial infections.
Box 1. Future questions in apoptotic cell removal in the
airspaces
•Does efferocytosis polarise airway macrophages to anM2 phenotype or
are M2 polarised airway macrophages better at efferocytosis?
• What is the impact of the tissue microenvironment on apoptotic cell
recognition receptor repertoires and outcome of their ligation?
• Is homeostatic apoptotic cell clearance different in requirements and
consequences to clearance of cells during inflammation?
• What is the impact of the altered lung environment in asthma, COPD
and CF on apoptotic cell clearance?
• Does cooperation between different apoptotic cell clearance receptors
introduce heterogeneity in outcome?
• Under what circumstances is efferocytosis by non-professional
phagocytes important?
• To what extent do PtdSer-expressing pathogens sculpt immunity?
• Should there be an effort to develop therapeutics that manipulate the
efferocytic pathway?
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